ONCOLYTICS BIOTECH INC.

Analyst Reco. Oncolytics Biotech Inc.

Equities

ONC

CA6823108759

Delayed Toronto S.E. Other stock markets 03:59:49 2024-05-16 pm EDT			5-day change	1st Jan Change
1.55 ^CAD	-1.27%		-8.28%	-13.41%

May. 15	Transcript : Oncolytics Biotech Inc. - Shareholder/Analyst Call
May. 15	Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Pancreatic Cancer Trial	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RBC on Oncolytics Biotech's Upcoming Type C Meeting With FDA	May. 13	MT
HC Wainwright Adjusts Price Target on Oncolytics Biotech to $5 From $15, Maintains Buy Rating	Nov. 13	MT
Oncolytics Biotech Brief: Announcing Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep "Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate"	23-06-05	MT
Oncolytics Biotech Inc. Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial That Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate	23-06-05	CI
JonesTrading Initiates Oncolytics Biotech at Buy With $9 Price Target	23-05-24	MT
Canaccord Genuity Adjusts Price Target on Oncolytics Biotech to $5 From $6, Maintains Buy Rating	23-03-06	MT
Oncolytics Biotech Inc. Reports Interim Results from Phase 1/2 Goblet Study Showing A 70% Objective Response Rate in Pancreatic Cancer At the SITC Annual Meeting	22-11-07	CI
Oncolytics Biotech Brief: Reporting Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting	22-11-07	MT
Maxim Initiates Oncolytics Biotech With Buy Rating, Sets Price Target at $3	22-10-06	MT
RBC Capital Keeps OutperformSpeculative on Oncolytics Biotech	22-03-04	MT
ONCOLYTICS BIOTECH : RBC Capital Keeps Outperform/Speculative Risk Rating, $6 TP on Oncolytics Biotech	21-03-12	MT
ONCOLYTICS BIOTECH : HC Wainwright Starts Oncolytics Biotech at Buy With $15 Price Target	21-02-17	MT
ONCOLYTICS BIOTECH : RBC Capital Keeps Outperform/Speculative Risk on Oncolytics Biotech After Q3	20-11-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW